Literature DB >> 26624608

Treatment of Attention Deficit Hyperactivity Disorder Accompanied by Epilepsy in a Child.

N Yucel1, A Yucel2, H Ozcan3.   

Abstract

Entities:  

Year:  2015        PMID： 26624608      PMCID： PMC4909090          DOI： 10.7727/wimj.2014.222

Source DB:  PubMed          Journal:  West Indian Med J        ISSN： 0043-3144            Impact factor:   0.171


× No keyword cloud information.
  5 in total

1.  Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.

Authors:  Stephan A Chalon; Jean-Pierre Desager; Karl A Desante; Reginald F Frye; Jennifer Witcher; Amanda J Long; John-Michael Sauer; Jean-Luc Golnez; Brian P Smith; Holly R Thomasson; Yves Horsmans
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

2.  Epilepsy in children with attention-deficit/hyperactivity disorder.

Authors:  Shanlee M Davis; Slavica K Katusic; William J Barbaresi; Jill Killian; Amy L Weaver; Ruth Ottman; Elaine C Wirrell
Journal:  Pediatr Neurol       Date:  2010-05       Impact factor: 3.372

3.  Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Authors:  Frank P Bymaster; Jason S Katner; David L Nelson; Susan K Hemrick-Luecke; Penny G Threlkeld; John H Heiligenstein; S Michelle Morin; Donald R Gehlert; Kenneth W Perry
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

Review 4.  Attention deficit disorder and epilepsy.

Authors:  Romaine Schubert
Journal:  Pediatr Neurol       Date:  2005-01       Impact factor: 3.372

5.  The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database.

Authors:  Andrew T McAfee; Karen C Holdridge; Catherine B Johannes; Kenneth Hornbuckle; Alexander M Walker
Journal:  Curr Drug Saf       Date:  2008-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.